900 related articles for article (PubMed ID: 10630955)
21. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
22. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations.
Olivero A; Ciancio A; Abate ML; Gaia S; Smedile A; Rizzetto M
J Viral Hepat; 2006 Jun; 13(6):355-62. PubMed ID: 16842437
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
25. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
[TBL] [Abstract][Full Text] [Related]
26. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
27. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus genotyping, core promoter, and precore/core mutations among Afghan patients infected with hepatitis B: a preliminary report.
Amini-Bavil-Olyaee S; Alavian SM; Adeli A; Sarrami-Forooshani R; Sabahi F; Sabouri E; Tavangar HR; Azizi M; Mahboudi F
J Med Virol; 2006 Mar; 78(3):358-64. PubMed ID: 16419114
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
[TBL] [Abstract][Full Text] [Related]
30. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region.
Maruyama T; Mitsui H; Maekawa H; Yamada H; Hirayama M; Iino S; Yasuda K; Koike K; Kimura S; Milich DR
Am J Gastroenterol; 2000 Oct; 95(10):2894-904. PubMed ID: 11051365
[TBL] [Abstract][Full Text] [Related]
31. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
32. Double point mutation in the core promoter region of hepatitis B virus (HBV) genotype C may be related to liver deterioration in patients with chronic HBV infection.
Nakashima H; Furusyo N; Kubo N; Kashiwagi K; Etoh Y; Kashiwagi S; Hayashi J
J Gastroenterol Hepatol; 2004 May; 19(5):541-50. PubMed ID: 15086598
[TBL] [Abstract][Full Text] [Related]
33. Gradual accumulation of mutations in precore core region of HBV in patients with chronic active hepatitis: implications of clustering changes in a small region of the HBV core region.
Hur GM; Lee YI; Suh DJ; Lee JH; Lee YI
J Med Virol; 1996 Jan; 48(1):38-46. PubMed ID: 8825708
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
35. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
36. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis.
Liang TJ; Hasegawa K; Rimon N; Wands JR; Ben-Porath E
N Engl J Med; 1991 Jun; 324(24):1705-9. PubMed ID: 2034247
[TBL] [Abstract][Full Text] [Related]
37. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B.
Oketani M; Oketani K; Xiaohong C; Arima T
J Med Virol; 1999 Aug; 58(4):332-7. PubMed ID: 10421398
[TBL] [Abstract][Full Text] [Related]
38. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
[TBL] [Abstract][Full Text] [Related]
40. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
